EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer

M Olazábal-Morán, C Blázquez-Barbadillo, E Pérez-Izquierdo, M Muñoz-Silva, A Garrido

Advanced Drug Delivery Reviews · 2026-06 · 233 · 115840

DOI: 10.1016/j.addr.2026.115840 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-06. Verfasst von M Olazábal-Morán und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nanocaging Research Group; Department of Biosciences; Faculty of Biomedical and Health Sciences; Universidad Europea de Madrid; Campus de Villavicios…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Precision Medicine, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 266 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Reactive Oxygen SpeciesPrecision MedicineLung NeoplasmsAntineoplastic AgentsHumansProteolysis Targeting ChimeraAnimals

Stichwörter der Autor:innen

Innovative therapyLung CancerParadoxical role of ROSPrecision medicineROS-activatable PROTACROS-related SMIsROS-related prodrugsReactive oxygen species (ROS)

Substanzen

Reactive Oxygen SpeciesProteolysis Targeting ChimeraAntineoplastic Agents

Autor:innen und Institutionen

  • Nanocaging Research Group; Department of Biosciences; Faculty of Biomedical and Health Sciences; Universidad Europea de Madrid; Campus de Villaviciosa, Calle Tajo s/n, 28670, Villaviciosa de Odón, Madrid, España.
  • Nanocaging Research Group; Department of Biosciences; Faculty of Biomedical and Health Sciences; Universidad Europea de Madrid; Campus de Villaviciosa, Calle Tajo s/n, 28670, Villaviciosa de Odón, Madrid, España. Electr…

Zitieren

APA

Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026). Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer. Advanced Drug Delivery Reviews, 233, 115840. https://doi.org/10.1016/j.addr.2026.115840

Vancouver

Olazábal-Morán M, Blázquez-Barbadillo C, Pérez-Izquierdo E, Muñoz-Silva M, Garrido A. Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer. Advanced Drug Delivery Reviews. 2026;233:115840. doi:10.1016/j.addr.2026.115840

BibTeX
@article{OlazbalMorn2026,
  author = {Olazábal-Morán, M and Blázquez-Barbadillo, C and Pérez-Izquierdo, E and Muñoz-Silva, M and Garrido, A},
  title = {Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {233},
  pages = {115840},
  doi = {10.1016/j.addr.2026.115840}
}
Kostenlos starten →